ABSTRACT: Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women’s health. CVD and breast cancer have several overlapping risk factors, such as obesity and smoking. Additionally, current breast cancer treatments can have a negative impact on cardiovascular health (e.g., left ventricular dysfunction, accelerated CVD), and for women with pre-existing CVD, this might influence cancer treatment decisions by both the patient and the provider. Improvements in early detection and treatment of breast cancer have led to an increasing number of breast cancer survivors who are at risk of long-term cardiac complications from cancer treatments. For older women, CVD poses a greater mortality threat than breast cancer itself. This is the first scientific statement from the American Heart Association on CVD and breast cancer. This document will provide a comprehensive overview of the prevalence of these diseases, shared risk factors, the cardiotoxic effects of therapy, and the prevention and treatment of CVD in breast cancer patients.
in cancer care, survivors could develop latent cardiac effects secondary to the cancer treatment, which can include chemotherapy, radiotherapy, and targeted therapy (eg, trastuzumab).5–7

The field of cardio-oncology has emerged in response to the need to provide the best cancer care without compromising cardiovascular health. Societal committees and new organizations have rapidly emerged to address patients’ needs, including clinical care, research, and education.8,9 Recent societal publications include a consensus statement regarding the training of future cardio-oncologists and guidelines regarding the monitoring and prevention of left ventricular (LV) dysfunction in adult cancer survivors.10,11

Hospitals have been developing and marketing collaborative cardio-oncologic programs to meet rising clinical demands in the field. Lack of formal clinical training programs, funding, and cardiovascular guidelines are some of the unmet needs that will need to be addressed over time to further advance CVD care of cancer patients.8 This scientific statement is the American Heart Association’s first on the connection between CVD and breast cancer. It aims to provide a comprehensive overview of the prevalence of these diseases, shared risk factors, and the cardiotoxic effects of cancer therapy, as well as review the prevention and treatment of CVD in breast cancer patients. Although treatment of cardiotoxicity is not within the scope of this statement, it is clearly an important aspect of cardio-oncology, and it too warrants further research and guideline development.

SCOPE OF THE PROBLEM

CVD and breast cancer are significant causes of morbidity and mortality in the United States. CVD affects ≈47.8 million women,1 and breast cancer affects ≈3.32 million women.12 On the basis of 2014 Centers for Disease Control and Prevention attributable mortality data in women, 1 in 3.3 deaths was attributed to CVD and 1 in 8.3 deaths was attributed to coronary heart disease (CHD), whereas 1 in 31.5 deaths was attributed to breast cancer.1 Mortality rates for CVD and breast cancer have decreased, with an average decline in CVD deaths (both sexes) by 6.7% per year from 2004 to 2014 and in female breast cancer deaths by 1.8% per year from 2005 to 2014.1,12 Direct annual medical costs in the United States are high: ≈$272.5 billion for CVD, $124.57 billion for all cancers, and $16.5 billion for breast cancer; moreover, these costs are expected to continue to rise.13,14

The lifetime risk of developing breast cancer in women is 12.4% based on 2012 to 2014 data. The rate of new female breast cancer cases was 124.9 per 100000 women per year, with a death rate of 21.2 per 100000 women per year.12 Nearly 90% of breast cancer patients survive at least 5 years after their initial diagnosis.12 Currently, there are ≈3 million breast cancer survivors in the United States15; however, older women are more likely to die of diseases other than breast cancer, and CVD is the most frequent cause.16,17 In older, postmenopausal women, the risk of mortality attributable to CVD is higher in breast cancer survivors than in women without a history of breast cancer. This greater risk manifests itself ≈7 years after the diagnosis of breast cancer, which highlights the need to reduce the additional burden of CVD during this time frame with early recognition and treatment of CVD risk factors.18

Influence of Race and Age

Age-adjusted death rates are higher for CHD and stroke than for breast cancer in non-Hispanic white and black females; however, when race was examined, the rates of CHD, stroke, and breast cancer were higher in non-Hispanic black women than in non-Hispanic white women and Hispanic women (Figure 1).1 There are similar racial-ethnic differences concerning the incidence and mortality rates of breast cancer, with non-Hispanic black women having the highest mortality.5 Non-Hispanic white women 60 to 84 years of age have a higher incidence of breast cancer than black women; however, in black women, the incidence of breast cancer is higher in those <45 years of age, and the mortality rate for breast cancer is higher at all ages.19 Furthermore, American Indian/Alaska Native, Hispanic, and Asian/Pacific Islander women have lower breast cancer incidence and mortality rates than non-Hispanic white and non-Hispanic black women. Additionally, compared with non-Hispanic white women, Hispanic and non-Hispanic black women are more likely to present with later stages of breast cancer,20 which in turn can have a negative impact on clinical outcomes.

The improved success of screening and treating breast cancer has contributed to the growing number of survivors, more than half of whom are >65 years of age.21 The prognosis of older breast cancer patients is affected by the effective management of preexisting comorbid conditions such as diabetes mellitus and hypertension.22 In older women diagnosed with breast cancer, CVD is the leading cause of mortality, and breast cancer is the second most common cause.23 Not surprisingly, comorbidities, including CVD, in older breast cancer patients have been associated with decreased overall survival.24 The identification and management of cardiovascular risk factors23 in this population is important because CVD, if not recognized and treated, can pose a greater health risk than the cancer itself.22 The expanding role of primary care physicians, oncologists, cardiologists, and allied healthcare providers in survivorship programs is essential to optimize the
management of comorbidities to realize the gains seen in breast cancer treatment.25–28

**COMMON RISK FACTORS**

Breast cancer and CVD share a number of common risk factors (Figure 2). Cardiovascular clinical care and research have focused on risk factors for >60 years, because it is believed that ≈80% of CVD can be prevented through risk factor modifications such as promoting a healthy diet, physical activity, and a healthy weight; abstinence from tobacco; blood pressure control; diabetes mellitus management; and a good lipid profile.32 Adherence to a larger number of ideal cardiovascular health behaviors or factors from the American Heart Association’s Life’s Simple 7 health campaign1 is associated with a trend toward a lower incidence of breast cancer (P for trend=0.11).33 The Cardiovascular Lifetime Risk Polling Project, involving 18 cohort studies, found that at age 45 years, individuals with optimal risk factor profiles have a significantly lower lifetime risk of CVD events than those with even 1 major risk factor (4.1% versus 20.2% among women). Having ≥2 risk factors further increased lifetime CVD risk to 30.7% in these women.34 Aggressive management of these cardiovascular risk factors can also substantially reduce the lifetime risk of developing cancer.35 Risk factors for breast cancer have only been discussed more recently, but there is growing awareness that through risk factor modification, some cases of breast cancer might be prevented.36,37

**Dietary Patterns**

Studies of the association between dietary patterns, CVD, and breast cancer typically compare a prudent or healthy dietary pattern (high in vegetables and fruits, poultry, fish, low-fat dairy products, and whole grains) with the Western diet or so-called unhealthy diet (red or processed meats, refined grains, sweets, and high-fat dairy products).38 The American Heart Association’s 2020 Impact Goals include a definition of cardiovascular health with a healthy diet pattern that is appropriate in energy balance and consistent with a Dietary Approaches to Stop Hypertension–type eating plan.39 Dietary habits also affect multiple established cardiovascular risk factors, including blood pressure, cholesterol levels, glucose levels, and obesity.32,40 The NHS (Nurses’ Health Study) found that a dietary pattern consisting of higher intake of vegetables, fruits, fish, poultry, and whole grains (prudent diet) was associated with a 28% lower cardiovascular mortality (relative risk [RR], 0.72; 95% confidence interval [CI], 0.60–0.87), whereas a dietary pattern consisting of higher intake of processed or red meats, refined grains, and sweets (Western diet) was associated with a 22% higher cardiovascular mortality (RR, 1.22; 95% CI, 1.01–1.48).41

In contrast, epidemiological data regarding dietary patterns are less consistent in breast cancer. Some reports support prudent dietary patterns as being inversely associated with risk of breast cancer,42–45 whereas others found no association.46–48 The link between breast cancer and a healthy or prudent diet might de-
depend on the tumor type. Among 86,261 women in the NHS, a diet high in fruits and vegetables, such as one represented by the Dietary Approaches to Stop Hypertension diet score, was associated with a lower risk of estrogen receptor (ER)–negative breast cancer. Furthermore, a diet high in plant protein and fat and moderate in carbohydrate content was associated with a lower risk of ER-negative breast cancer.

Studies of the link between the Western diet and breast cancer have shown positive, negative, or no associations. The relationship between the frequency of consumption of energy-dense foods and fast foods and breast cancer risk was examined in black and white women. Higher consumption of energy-dense foods and fast foods was associated with increased breast cancer risk in both racial groups, with some differences by menopausal and ER status of the tumor. Adjustment for total energy intake attenuated odds ratios (ORs) in black women but strengthened risk estimates in white women. The relationship with frequency of fast food intake was stronger among premenopausal black women and postmenopausal white women, for whom a positive trend was also observed with frequent intake of energy-dense foods and sugary drinks. Adjustment for total energy intake attenuated odds ratios (ORs) in black women but strengthened risk estimates in white women.

In the WHI (Women’s Health Initiative) dietary modification clinical trial of 49,835 women, reduction of total fat consumption from 37.8% of energy at baseline to 24.3% at 1 year and 28.8% at 6 years had no effect on incidence of major CHD (RR, 0.98; 95% CI, 0.88–1.09) or total CVD (RR, 0.98; 95% CI, 0.92–1.05) over a mean of 8 years. The WHI dietary modification trial of a low-fat, high fruit and vegetable diet also failed to provide a definitive answer as to whether fat intake modifies breast cancer risk (hazard ratio [HR], 0.91; 95% CI, 0.83–1.01 for intervention versus control group after 8 years of follow-up). Another randomized trial of reduced fat intake and increased carbohydrate intake in women who were followed for 10 years found no effect of fat intake but an increased risk of ER-positive breast cancer with lower carbohydrate intake. In a 20-year follow-up of the NHS, there was no association between fats and breast cancer risk, even when subtypes of fats were considered. However, the RR for breast cancer in premenopausal women in the NHS was 1.35 in the highest quartile of dietary fat intake compared with the lowest quartile (OR, 1.35; 95% CI, 1.00, 1.81).

Blood plasma lipid levels are influenced by diet and weight as well and have been associated with breast
cancer risk. In a cohort of 4670 women with increased mammographic density, higher levels of serum high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 were associated with increased risk of developing breast cancer (23% and 28%, respectively), whereas higher levels of non-HDL-C and apolipoprotein B were associated with a lower risk of developing breast cancer (19% and 22%, respectively), when compared with the reference group.67 These results demonstrated a possible link between lipids and breast cancer risk, specifically in women with increased mammographic density. The impact of cardiovascular risk reduction strategies on HDL-C and on breast cancer risk needs further study.

**Alcohol Consumption**

Meta-analyses of epidemiological studies have shown both beneficial and detrimental associations between alcohol intake and all-cause mortality in women, which is a function of the level of consumption and age.68 Observational data from 34 cohort studies demonstrated an association of moderate alcohol intake with reduced all-cause mortality, and in this report, alcohol intake of 5 g/d (a standard alcoholic drink contains 14 g of alcohol) was associated with an 18% reduction in all-cause mortality.69 However, the relationship between alcohol consumption and ischemic heart disease (IHD) is complex. In the NHS, light to moderate alcohol consumption (5 g/d) was associated with a lower risk of total stroke than for nondrinkers (RR, 0.83; 95% CI, 0.75–0.92).70 Several meta-analyses of observational studies show evidence for a cardioprotective association of average alcohol intake on IHD risk.71–73 More recently, a systematic review of 44 observational studies found that in women, a steep J-curve was observed for IHD mortality and morbidity, with the lowest risk shown at 11 g of alcohol per day and no cardioprotection at 14 g/d.74 Data from 8 prospective studies revealed an inverse relationship between alcohol intake and CHD. There was a significantly lower risk of CHD among women (mean age, 50 years) with an alcohol intake of up to 30 g/d (RR, 0.58; 95% CI, 0.49–0.68) compared with nondrinkers; however, higher levels of daily alcohol intake did not confer additional CVD benefit.75 However, no beneficial effect on IHD was seen with episodic and chronic heavy alcohol drinking.76

Although low to moderate intake of alcohol might decrease the risk for CHD, there are no cancer-related benefits of modest drinking.35 Alcohol consumption is a well-established, modifiable risk factor for breast cancer.76,77 There is considerable variability on how alcohol intake is defined, and this makes direct comparisons between studies difficult. Epidemiological studies, including the WHI,78 support the positive relationship between alcohol and breast cancer risk.79–82 Meta-analyses suggest a 5% to 9% increase in risk per drink per day, or ≤12.5 g/d.83–87 Consuming ≥2 alcoholic drinks per day for 5 years is associated with an 82% increased breast cancer risk compared with no alcohol intake.88 In the NHSII (Nurses’ Health Study II), the risk of breast cancer was 34% higher (RR, 1.34; 95% CI, 1.00–1.80) among women 24 to 44 years of age with alcohol intake of ≥15 g/d (=1.5 drinks per day) compared with women who abstained from alcohol before first pregnancy.89 There was a dose-response relationship between alcohol intake before first pregnancy and breast cancer risk, with an RR of 1.11 (95% CI, 1.00–1.23) for each additional 10-g/d intake; there was no such relationship for alcohol consumption and breast cancer after the first pregnancy. Furthermore, in the NHS, the risk of breast cancer was increased by 21% in adult binge drinkers compared with nondrinkers after controlling for cumulative alcohol intake.82

Breast cancer is a heterogeneous disease with many subtypes defined by hormone receptor status and histological type. The elevated levels of intracellular estrogens resulting from alcohol intake might act through the ER to promote breast cancer.76 Epidemiological studies have shown that the relationship between alcohol intake and hormone receptor–positive breast tumors was stronger than with other types of breast cancer.85 Compared with never-drinkers, HRs for premenopausal women who consumed ≥7 drinks per week were as follows: for ER-positive breast cancer, 1.48 (95% CI, 1.19–1.83); for progesterone receptor (PR)–positive cancer, 1.64 (95% CI 1.31–2.06); and for mixed/ductal/lobular cancer, 2.51 (95% CI, 1.20–5.24).90 The risks for ER-positive/PR-positive and ER-positive/PR-negative breast cancer increased by 8% (95% CI, 2%–15%) and 12% (95% CI, 0%–25%), respectively, per drink per day among postmenopausal women,91 which is comparable to the 12% increase in risk of ER-positive tumors per 10 g/d of alcohol intake reported in a meta-analysis of prospective and case-control studies.85

**Meat Consumption**

The association between meat consumption and breast cancer is not well understood. Among a large cohort of women in the United Kingdom, increased consumption of total and nonprocessed meat was associated with a higher risk of premenopausal breast cancer, and total processed meat and red meat consumption was positively associated with postmenopausal breast cancer.92 A case-control study found that processed meat intake, even just 1 or 2 times per week, was associated with a 2.7-fold (OR, 2.65; 95% CI, 1.36–5.14; P = 0.004) higher likelihood of developing breast cancer, but red, white, and grilled meat intake was not.93 A study of 4684 French women found that processed meat intake was associated with higher breast cancer risk (HR, 1.45; 95% CI, 0.92–2.27), and this association was stronger when cooked ham was excluded and manifested only in women who were not taking antioxidant
supplements. Among the 44,231 participants of the NHSII cohort, greater consumption of red meat in adolescence was significantly associated with higher premenopausal breast cancer risk (highest versus lowest quintiles: RR, 1.43; 95% CI, 1.05–1.94) but not postmenopausal breast cancer. Others have found weak positive associations between meat consumption and breast cancer. Several studies have linked red and processed meat intake with increased mortality and acute coronary events.

Collectively, the evidence for the influence of diet on breast cancer and CVD risk is mixed. The results of epidemiological studies must be interpreted cautiously, because these studies cannot determine causation. The sample size, measurement error in nutrients and in outcome variables, and individual variation in human genetics and lifestyle factors limit the ability to measure the effect of diet on breast cancer. This is largely because of uncontrolled confounding factors and differences in study designs and measurement of end points. It appears that dietary factors are particularly important in determining premenopausal breast cancer risk. Likewise, there is increasing evidence to suggest the importance of alcohol consumption in the development of breast cancer. Understanding the impact of diet on breast cancer risk will require examination of gene-environment interactions and long-term epigenetic mechanisms. Some promising work has found that gut microbiota is less diverse and compositionally different in postmenopausal women with breast cancer than in similar women without breast cancer. Breast cancer risk can be affected by obscure early-life effects that are transmitted through the maternal line. It is plausible that the infant’s gut microbiota composition could influence breast cancer risk in adulthood.

**Physical Activity**

About 150 minutes of moderate-intensity physical activity per week is recommended for all Americans. Only 17.6% of American women meet these physical activity guidelines. Strong evidence supports the elevated risk that inactivity (<150 min/wk) poses for both CVD and breast cancer. Globally, physical inactivity is believed to be responsible for 12.2% of the burden of myocardial infarction after accounting for other CVD risk factors including cigarette smoking, hypertension, obesity, dyslipidemia, alcohol, and psychosocial factors. A meta-analysis of longitudinal studies of women found that the RR of incident CHD were 0.83 (95% CI, 0.69–0.99), 0.77 (95% CI, 0.64–0.92), 0.72 (95% CI, 0.59–0.87), and 0.57 (95% CI, 0.41–0.79) across increasing quintiles of physical activity compared with the lowest quintile. Women in the CARDIA study (Coronary Artery Risk Development in Young Adults) who maintained high physical activity through young adulthood gained about 6 fewer kilograms of weight and about 3.8 fewer centimeters in waist circumference in middle age than those with lower activity. Similarly, among US women, every additional daily hour of television watching was associated with 0.3 lb of greater weight gain every 4 years, whereas every hour per day of less television watching was associated with a similar amount of relative weight loss. A study of >1 million women followed up over 9 years found that moderate physical activity but not strenuous physical activity was associated with lower risk of CHD or a cardiovascular event. Conversely, in a population-based study in Australia, among adults followed up for 6 years and reporting any moderate to vigorous physical activity, the proportion of vigorous activity showed an inverse dose-response relationship with all-cause mortality compared with those reporting no vigorous activity.

Studies have consistently shown that moderate to vigorous physical activity is associated with a decreased breast cancer risk among both premenopausal and postmenopausal women who are more active versus those who are less active. Several mechanisms have been proposed for how physical activity potentially reduces breast cancer risk, including reduced exposure to estrogen and androgens, insulin-related factors, adipokines, and inflammation. A meta-analysis of 29 observational studies found a significant reduction in breast cancer risk among the most physically active compared with the least active women. A more recent meta-analysis of 22 studies involving 123,574 participants found an inverse relationship between physical activity and breast cancer events and deaths. Compared with those who reported low or no lifetime recreational prediagnosis physical activity, those who reported high lifetime recreational physical activity had a significantly lower risk of breast cancer–related death (HR, 0.73; 95% CI, 0.54–0.98). Additionally, significant risk reduction for breast cancer–related death was demonstrated in women who had engaged in recreational physical activity more recently before diagnosis (HR, 0.84; 95% CI, 0.73–0.97). In NHSII, data showed that physical activity at ages 14 to 17 years was associated with a 15% lower risk of premenopausal breast cancer.

**Sedentary Lifestyle**

Sedentary behavior is defined as activities performed in a sitting or reclining posture with an energy expenditure typically in the range of 1.0 to 1.5 times the basal metabolic rate. Sedentary behavior is also characterized by prolonged sitting or lying down and absence of whole-body movement, such as watching television or other forms of screen-based entertainment and car driving. Previous research suggests that sedentary behavior has been associated with CVD and breast cancer.
pared with <5 hours each day was associated with increased CVD risk (HR, 1.18) in multivariable models that included physical activity. Low physical activity was also linked with higher CVD risk.122 Sedentary behavior has also been associated with high breast density, which has been shown to be a strong, independent risk factor for breast cancer, with a 4- to 6-fold increased risk compared with the least dense breasts.123,124 A case-control study found that for women in the highest quartile of physical activity compared with those in the lowest quartile, time spent in moderate to vigorous activity (measured by accelerometer) was inversely associated with risk of developing breast cancer after adjustment for known risk factors, sedentary behavior, and time spent wearing the accelerometer. They also found that sedentary behavior was positively associated with breast cancer, independent of moderate to vigorous activity (OR, 1.81; 95% CI, 0.27–0.56; P trend<0.001). In the Southern Community Cohort Study, sedentary behavior for ≥12 h/d compared with <5.5 h/d was associated with increased odds of breast cancer among white women (OR, 1.94; 95% CI, 1.01–3.70) but not black women (OR, 1.23; 95% CI, 0.82–1.83) after adjustment for physical activity (measured as metabolic equivalent hours per day).126 The racial differences noted in this study might be explained by variation in determining physical activity and underlying biological mechanisms that impact breast cancer risk. Independent of one another, sedentary behavior and physical inactivity are risk factors for breast cancer among white women. Reducing sedentary behavior and increasing physical activity are potentially independent targets for breast cancer prevention interventions.

Obesity, Overweight, and Body Mass Index

Overweight and obesity (body mass index [BMI] of ≥25 and ≥30 kg/m², respectively) are major risk factors for CVD121; furthermore lifetime obesity and physical inactivity increase the risk of CVD. Severe obesity (class III, body mass index ≥40 kg/m²) may pose an even greater CVD risk than class I or class II obesity.128 Among women in the WHI (n=156 775) with severe obesity compared with normal BMI, HRs (95% CIs) for mortality were on the order of 1.5 to 2.6 across black, Hispanic, and white women. For CHD, HRs were 2- to nearly 3-fold higher. However, CHD risk was strongly related to CVD risk factors across BMI categories even in severe obesity, and CHD incidence was similar by race/ethnicity when adjusted for differences in BMI and CVD risk factors.128 A meta-analysis of white adults over a mean follow-up of 10 years reported that among women, overweight and obese status (and perhaps underweight) based on BMI correlated with elevated all-cause death.129

Obesity is also a factor that is associated with breast cancer risk specifically in postmenopausal women.130,131 The relationship between obesity and breast cancer is complex. A dose-response meta-analysis found that each 5-kg increase in adult weight gain was associated with an 11% increased risk of postmenopausal breast cancer among nonusers of hormone replacement therapy (HRT; RR, 1.11; 95% CI, 1.08–1.13); there was no evidence of a linear relationship for premenopausal breast cancer (RR, 0.99; 95% CI, 0.95–1.03).132 Furthermore, higher BMI (overweight-to-obese category) among women at age 18 years was associated with a 24% lower risk of breast cancer in premenopausal women compared with low BMI (95% CI, 0.60, 0.96, P trend=0.09).133 A BMI in the morbidly obese category, compared with normal- to low-weight BMI, was associated with a 19% reduced breast cancer risk (95% CI, 0.61–1.06; P trend=0.05) in premenopausal women. A meta-analysis of case-control and cohort studies of premenopausal women found an inverse relationship between BMI and breast cancer risk. There was a 5% reduced risk for developing premenopausal breast cancer with a 5-kg/m² increase in BMI.134 Stratified by ethnicity, the inverse association remained for black (RR, 0.95; 95% CI, 0.91–0.98) and white women (RR, 0.93; 95% CI, 0.91–0.95) but not for Asian women. However, for waist-hip ratio, the dose response showed a statistically significant increase in RR of 8% for each 0.1 increment, with the largest association detected in Asian women (19%; RR, 4.19; 95% CI, 1.15–1.24).134 Investigators of the NHS and NHSII observed that childhood and adolescent body fatness was significantly associated with a 20% to 50% decreased breast cancer risk throughout life, regardless of menopausal status.135 More recently, investigators of the NHS evaluated the link between recent weight change and total premenopausal and postmenopausal invasive breast cancer and hormone receptor status subtypes while controlling for average BMI before and after menopause.136 Short-term weight change was significantly associated with breast cancer risk (RR, 1.20; 95% CI, 1.09–1.33) for a 4-year weight gain of ≥15 lb versus no change (≤15 lb). The association was stronger for premenopausal women (RR, 1.38; 95% CI, 1.13–1.69) than for postmenopausal women (RR, 1.10; 95% CI, 0.97–1.25). Premenopausal short-term weight gain had a stronger association for ER-positive/PR-negative (RR per 25-lb weight gain, 2.19; 95% CI, 1.33–3.61) and ER-negative/PR-negative breast cancer (RR per 25-lb weight gain, 1.61; 95% CI, 1.09–2.38) than for ER-positive/PR-positive breast cancer (RR per 25-lb weight gain, 1.13; 95% CI, 0.89–1.43). This study supported the deleterious effects of short-term weight gain, particularly before menopause, even after controlling for average BMI before and after menopause.136 Regardless of levels of adolescent physical activity, early-life body

Circulation. 2018;137:00–00. DOI: 10.1161/CIR.0000000000000556
leanness of 74,723 women in the NHSII was significantly associated with higher breast cancer risk; the association was slightly attenuated among those who were active during adolescence compared with those who were inactive. Increased breast cancer risk among postmenopausal women who had adolescent leanness was confined to those who gained excess weight during adulthood.

Tobacco Use

Although cigarette smoking is a major risk factor for CVD and stroke, the link between cigarette smoking and breast cancer remains inconclusive. A meta-analysis comparing pooled data of ≈2.4 million smokers and nonsmokers found that the RR for smokers compared with nonsmokers for developing CHD was 25% higher in women than in men (95% CI, 1.12–1.39). The association between smoking and breast cancer risk has been evaluated extensively in epidemiological studies, with an emerging consensus for a weak, positive association. One large Canadian study found a non-significant trend toward increased breast cancer risk in premenopausal women who were active smokers or began smoking before their first pregnancy. Moreover, several studies reported an increased breast cancer risk associated with smoking for long durations and initiation early in life. The association between passive or sidestream smoke and breast cancer is also mixed. Some reports have found an association, whereas others have not. Genetic variants in enzymes involved in the metabolism of carcinogens are postulated to modify the association between smoking and breast cancer risk. More recent meta-analyses report a significant interaction between smoking and carcinogen-metabolizing genotype variants (eg, NAT2). Smokers carrying the slow acetylator variant NAT2 genotypes had an increased breast cancer risk, and among women with high-pack-years of smoking exposure, the NAT2 slow acetylator variant genotypes were associated with an increased breast cancer risk.

Age

The incidence of breast cancer increases with advancing age, doubling approximately every 10 years until menopause is reached, at which time the rate of increase slows. The incidence of CVD increases steadily with advancing age, but the rate of increase becomes steeper at menopause, rather than slowing. Age is obviously not changeable, so its role in prevention is as a risk predictor rather than a modifiable risk factor.

Age at Menarche and Menopause

In addition to age in general, age of menarche and menopause is an additional age-related risk factor for both breast cancer and CVD. Women who start menstruating earlier in life (early menarche) have an increased risk of developing breast cancer. These women also have a higher risk for developing CVD, particularly in nonsmoking populations. In terms of menopause, women who undergo menopause earlier in life (early menopause) have an increased risk of developing CVD but a decreased risk of developing breast cancer. Women undergoing menopause after the age of 55 years are twice as likely to develop breast cancer as women who undergo menopause before the age of 45.

Postmenopausal HRT

Several studies have shown an association between postmenopausal hormone use and risk of breast cancer. The NHS study followed >100,000 healthy women 30 to 50 years of age at the time of enrollment and found that the risk of developing breast cancer was 1.2 to 2 times greater for women who reported ≥5 years of current use of HRTs than for those who never used HRT. Long-term cumulative follow-up data of postmenopausal women with hysterectomy from the WHI demonstrated a 45% lower risk of breast cancer-related mortality in those randomized to estrogen-only therapy than in those given placebo. However, postmenopausal women with an intact uterus who were randomized to combination therapy of estrogen plus progestin had a 44% increase in breast cancer mortality compared with those in the placebo arm, although this result did not meet statistical significance. Several studies have now also reported that HRT is associated with an increased risk of CVD in older postmenopausal women and women with CHD. The largest of these studies is the WHI, which randomized >16,000 postmenopausal women (average age 63.3±7.1 years) with no history of coronary artery disease to receive either estrogen alone, estrogen combined with progesterone, or placebo and then followed them for an average of 5.6 years. The estrogen plus progesterin arm was prematurely terminated (after 5.2 years of follow-up), and at the time of study discontinuation, there was an increased risk of CHD with HRT (HR, 1.29; nominal 95% CI, 1.02–1.63). These data confirm that postmenopausal HRT is associated with both breast cancer and CVD (stroke, thromboembolic events, CHD), and this is a potentially modifiable risk factor for both diseases.

Genetics

Clinical and population-based studies have demonstrated that genetic factors play important roles in both breast cancer and CVD, and genes involved in the development of breast cancer and CVD have been iden-
Figure 3. Factors associated with developing CVD and breast cancer.

Impact of these factors in a positive (green downward arrow, reduced risk) or negative (red upward arrow, increased risk) on developing CVD or breast cancer.19-31 CVD indicates cardiovascular disease.

ified. Two breast cancer susceptibility genes (BRCA1 and BRCA2) are thought to account for between 5% and 10% of all breast cancer cases.164 Genetics plays a role in therapies as well. Therapies have been developed to target genes shown to be important in progression of breast cancer, such as the HER2 (c-erbB-2) oncogene.165 These discoveries have greatly enhanced our ability to detect and treat breast cancer. Although genes involved in the development of CVD have also been identified,166-168 we have not been able to identify a single gene responsible for a substantial proportion of cases, such as with the relationship of BRCA1 and BRCA2 to breast cancer. Animal studies have demonstrated an important role of the BRCA1 and BRCA2 genes in cardiac injury responses and an increased susceptibility of mice harboring the cardiomyocyte-specific BRCA mutation to develop HF after anthracycline exposure.169 However, human studies in women who are BRCA mutation carriers did not identify a higher risk of HF, hypertension, arrhythmias, myocarditis, pericarditis, left ventricular dysfunction, heart failure, myocardial ischemia, atrial fibrillation, ventricular tachycardia, ventricular failure, myocarditis, pericarditis, atrial fibrillation, ventricular tachycardia, and pericardial disease, arrhythmias.

Although most of the risk factors that are common to both CVD and breast cancer move risk in the same direction (ie, decrease or increase risk in both diseases), a few risk factors move risk in opposite directions (Figure 3). Decreased risk for developing CVD but increased risk for developing breast cancer was associated with low to moderate alcohol intake, whereas increased risk for CVD but decreased risk for breast cancer was associated with early menopause and premenopausal obesity. Knowledge and understanding of the risk factors for CVD and breast cancer will contribute to a better understanding of how best to prevent both diseases.

### Table 1. Cancer Treatment and Cardiovascular Adverse Effects

<table>
<thead>
<tr>
<th>Cancer Treatment</th>
<th>Cardiovascular Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthracyclines (eg, doxorubicin, epirubicin)</td>
<td>Left ventricular dysfunction, heart failure, myocarditis, pericarditis, atrial fibrillation, ventricular tachycardia, ventricular fibrillation</td>
</tr>
<tr>
<td>Alkylating agents (eg, cisplatin, cyclophosphamide)</td>
<td>Left ventricular dysfunction, heart failure, myocarditis, pericarditis, arterial thrombosis, bradyarrhythmia, atrial fibrillation, supraventricular tachycardia</td>
</tr>
<tr>
<td>Taxanes (eg, paclitaxel)</td>
<td>Bradyarrhythmia, heart block, ventricular ectopy</td>
</tr>
<tr>
<td>Antimetabolites (eg, 5-fluorouracil, capecitabine)</td>
<td>Coronary thrombosis, coronary artery spasm, atrial fibrillation, ventricular tachycardia, ventricular fibrillation</td>
</tr>
<tr>
<td>Endocrine therapy (eg, tamoxifen, anastrozole, letrozole)</td>
<td>Venous thrombosis, thromboembolism, peripheral atherosclerosis, dysrhythmia, valvular dysfunction, pericarditis, heart failure</td>
</tr>
<tr>
<td>HER-2–directed therapies (eg, trastuzumab, pertuzumab)</td>
<td>Left ventricular dysfunction, heart failure</td>
</tr>
<tr>
<td>Cyclin-dependent kinase 4/6 inhibitors (eg, palbociclib, ribociclib)</td>
<td>QTc prolongation</td>
</tr>
<tr>
<td>Radiation therapy</td>
<td>Coronary artery disease, cardiomyopathy, valvular disease, pericardial disease, arrhythmias</td>
</tr>
</tbody>
</table>

Potential cardiotoxicities of breast cancer treatment. QTc indicates corrected QT interval.

### CARDDIOVASCULAR EFFECTS OF CANCER THERAPY

Cancer treatment can result in early or delayed cardiotoxicity that can vary from LV dysfunction to overt HF, hypertension, arrhythmias, myocardial ischemia, valvular disease, thromboembolic disease, pulmonary hypertension, and pericarditis. The most commonly reported and monitored side effect of chemotherapy is LV systolic dysfunction.171 Arrhythmias, independent of other concurrent cardiac disease, can occur from breast cancer treatment, including chemotherapy and radiation therapy (RT).172 Several chemotherapeutic agents can also prolong QT intervals.173 The absence of a clear consensus in definitions of cardiotoxicity makes it difficult to compare results of cardiac end points between clinical trials and furthermore makes the applicability of these findings in the real world challenging at best. This section will briefly review the pathophysiological mechanisms and resultant adverse cardiovascular effects of common therapies for breast cancer (Table 1).

#### Chemotherapeutic Agents

**Anthracyclines**

Anthracyclines, such as doxorubicin, have been used successfully in the treatment of various neoplasms such as breast cancer since the 1970s, but their use can result
in significant irreversible LV dysfunction. Doxorubicin interacts with DNA, intercalating and inhibiting macromolecular biosynthesis and inhibiting the progression of the topoisomerase IIβ within cardiac myocytes. By intercalating into the DNA, the anthracyclines bind to topoisomerase IIβ and disrupt replication, causing myocyte cell death.174,175 Another central mechanism that has been postulated is the generation of reactive oxygen species, which damage DNA, proteins, and lipids, including the mitochondrial membrane, and accelerate myocyte death.176 Anthracyclines also form complexes with intracellular iron, which in turn generate oxygen radicals. Interestingly, individuals with higher iron stores exhibit increased anthracycline toxicity.177

The myocardial toxicity of the anthracyclines can manifest early or late after exposure. The early manifestations could be related to inflammation resulting in a pericarditis-myocarditis syndrome,178 whereas the late manifestations are related to actual myocyte damage that results in the clinical syndrome of HF. Cell death has been confirmed by rising troponin levels.179 The risk of HF increases with increasing cumulative doses of anthracyclines; for instance, with doxorubicin, there is an ≈5% risk at a dose of 400 mg/m², a 26% risk at a dose of 550 mg/m², and up to a 48% risk at a cumulative dose of 700 mg/m².

However, there is no “safe dose” threshold, because individuals exposed to lower doses of anthracycline (<400 mg/m²), particularly those with underlying cardiovascular risk factors, are also at risk of experiencing cardiotoxicity.180–182 Most at risk for anthracycline-mediated cardiotoxicity are older patients, those with a prior cardiac pathology, and those who have been exposed to concomitant chemotherapy or RT (Table 2).11,183–185 Detailed cardiovascular phenotyping has suggested that on average, there are modest but persistent declines in LV ejection fraction (LVEF) of ≈4% even at 3 years after anthracycline exposure.186 LV functional recovery and reduction in cardiac events might be possible with early detection and prompt treatment of LV dysfunction; however, complete LVEF recovery was not seen in patients treated >6 months after completion of chemotherapy.187

Doxorubicin-based adjuvant chemotherapy for breast cancer has been found to cause arrhythmias and conduction abnormalities in 2.6% of patients versus 1% of patients who did not receive doxorubicin.188 Anthracyclines are associated with atrial fibrillation (2%–10%), which can occur acutely during or after chemotherapy.189 An individualized patient-centered approach to decisions regarding the use of antithrombotic agents in the management of atrial fibrillation is recommended, with careful consideration of the benefits and risks of treatment.171,190 Ventricular tachycardia and ventricular fibrillation are less likely to be associated with anthracycline treatment.189 The burden of arrhythmias detected on defibrillators in patients with anthracycline-induced cardiomyopathy is similar to those with other forms of cardiomyopathy (non-anthracycline chemotherapy or IHD), with nonsustained ventricular tachycardia as the most common arrhythmia, followed by atrial fibrillation and then sustained ventricular tachycardia/ventricular fibrillation.191 A small study of long-term survivors with childhood cancers treated with anthracyclines, especially with concomitant chest radiation, found that prior anthracycline therapy was associated with a prolonged corrected QT interval of 0.43 or higher, but no torsade de pointes was documented.188

Structural analogues of doxorubicin, such as epirubicin (commonly used in Europe and Canada), were suggested to have lower clinical cardiotoxicity than doxorubicin (OR, 0.39; 95% CI, 0.2–0.78).192 However, a recent Cochrane database review of 5 randomized trials (1036 patients) comparing doxorubicin and epirubicin did not find a statistically significant difference in HF incidence between the 2 regimens (RR, 0.36; 95% CI, 0.12–1.11),193 and therefore, epirubicin should not be perceived as cardioprotective or less cardiotoxic.

Alkylating Agents

Alkylating agents, including cisplatin and cyclophosphamide, can also damage DNA, resulting in cytotoxicity and myocyte death. Histopathology shows interstitial hemorrhage, edema, and necrosis. Cyclophosphamide has been the alkylating agent most commonly used in the treatment of breast cancer. Clinical cardiotoxicity with cyclophosphamide is extremely rare, can occur within 10 days of administration, and appears to be related to prior anthracycline therapy or mediastinal

---

**Table 2. Risk for Developing Cardiac Dysfunction**

<table>
<thead>
<tr>
<th>At-risk therapies including any of the following:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>High-dose anthracycline therapy: doxorubicin ≥250 mg/m² or epirubicin ≥600 mg/m²</td>
<td></td>
</tr>
<tr>
<td>High-dose radiation therapy when heart is in the field of treatment: radiotherapy ≥30 Gy</td>
<td></td>
</tr>
<tr>
<td>Sequential treatment: lower-dose anthracycline therapy (doxorubicin &lt;250 mg/m² or epirubicin &lt;600 mg/m²) and then subsequent treatment with trastuzumab</td>
<td></td>
</tr>
<tr>
<td>Combination therapy: lower-dose anthracycline (doxorubicin &lt;250 mg/m² or epirubicin &lt;600 mg/m²) combined with lower-dose radiation therapy when heart is in the field of treatment (&lt;30 Gy)</td>
<td></td>
</tr>
<tr>
<td>Presence of any of the following risk factors in addition to treatment with lower-dose anthracycline or trastuzumab alone:</td>
<td></td>
</tr>
<tr>
<td>Older age at time of cancer treatment (≥60 y)</td>
<td></td>
</tr>
<tr>
<td>≥2 CVD risk factors during or after cancer treatment: diabetes mellitus, dyslipidemia, hypertension, obesity, smoking</td>
<td></td>
</tr>
<tr>
<td>History of myocardial infarction, moderate valvular disease, or low-normal left ventricular function (50%–55%) before or during cancer treatment</td>
<td></td>
</tr>
</tbody>
</table>

Cancer patients are considered to be at an elevated risk for developing cardiac dysfunction if they meet any of the criteria in this Table. For additional information on other risk factors and management strategies, see the American Society of Clinical Oncology guidelines.11,183–185

Adapted with permission from Armenian et al.11 Copyright © 2016, American Society of Clinical Oncology. All rights reserved.

---

```
<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEF</td>
<td>0.50</td>
</tr>
<tr>
<td>Correction QT interval</td>
<td>0.43</td>
</tr>
<tr>
<td>HF incidence</td>
<td>0.36</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.12–1.11</td>
</tr>
</tbody>
</table>
```

---

Downloaded from http://circ.ahajournals.org/ by guest on February 5, 2018
radiation. Myocarditis and pericarditis have also been described but are rare. Bradycardia, supraventricular tachycardia, and atrial fibrillation have also been reported in patients receiving systemic alkylating agents.

**Taxanes**

Taxanes, such as paclitaxel, act as microtubule poisons and block mitotic cycle progression by affecting microtubule processes and producing abnormal spindles and by disrupting mitosis, which results in apoptosis. Taxanes are important agents in the treatment of early and advanced breast cancer. Taxanes can be given sequentially or in combination with anthracyclines in early-stage breast cancer. Sequencing of taxanes alters the pharmacokinetics of anthracyclines but is not known to directly result in HF.

Administration of paclitaxel has been associated with bradycardia; 29% of patients in the phase II paclitaxel clinical trials experienced heart rates <40 bpm. Other rhythm disturbances noted in patients with rhythm monitoring were asymptomatic left bundle-branch block and nonsustained ventricular tachycardia, which was also noted when paclitaxel was combined with cisplatin. It is unclear whether the rhythm disturbances observed with paclitaxel might have been caused by the formulation vehicle, polyethoxylated castor oil, or premedication with H₁ and H₂ antagonists to prevent hypersensitivity reactions.

**Antimetabolite Drugs**

The antimetabolite drugs, in particular 5-fluorouracil (5-FU) and capecitabine (a prodrug that is enzymatically converted to fluorouracil in the tumor), are pyrimidine analogues that disrupt DNA and RNA synthesis. These agents have been used as first-line therapy (capecitabine alone or intravenous 5-FU in combination with other cytotoxic agents) for metastatic breast cancer and in combination with anthracyclines (5-FU, epirubicin, cyclophosphamide) in early-stage breast cancer. The most commonly described cardiac side effect is chest pain; however, myocardial infarction, HF, and arrhythmias have been reported, albeit rarely. Mechanisms that have been attributed to the chest pain include thrombosis or coronary arterial vasospasm. These symptoms usually resolve by stopping the drug infusion. Patients without coronary artery disease can also develop ischemia but at a much lower incidence than in those with pretreatment coronary artery disease (1.1% versus 4.5%). Cardiotoxicity incidence varies in the literature, ranging between 1% and 68% with 5-FU, and can occur early after treatment because of high, continuous-infusion doses, which is rare in the treatment of breast cancer.

Cardiotoxicity (vasospasm) with 5-FU can occur in the acute setting (during intravenous infusion) or can be delayed (2–5 days after administration). Long-term cardiotoxicity with 5-FU is uncommon. Other reported risk factors for cardiotoxicity with 5-FU include previous mediastinal RT, antecedent history of CVD, and concurrent use of combination chemotherapeutic agents. Arrhythmias induced by 5-FU and capecitabine, including ventricular tachycardia and ventricular fibrillation, are mostly ischemic in origin and usually occur in the context of coronary artery spasm; however, there are also reported cases of atrial fibrillation, atrial/ventricular ectopy, and QT prolongation.

**Endocrine Therapy**

Endocrine therapy has an important role in the treatment of patients with breast cancer expressing ER or PR. In early-stage hormone receptor–positive breast cancer, use of adjuvant tamoxifen or aromatase inhibitors (AIs) reduces cancer recurrence rates, improves overall survival, and is recommended by the current clinical practice guidelines. Hormonal therapies act by interrupting the cellular processes through which estrogen promotes growth of normal and cancerous tissue, and importantly, the differences in their molecular targets determines their cardiovascular and overall side-effect profile. Two main strategies are interference with estrogen signaling by competitive binding to ER, represented by tamoxifen, and inhibition of endogenous estrogen production, as in the case of AIs. In the adjuvant setting, endocrine therapy is prescribed for an extended period, often 25 years, which emphasizes the importance of detailed evaluation of its overall toxicity and cardiovascular side-effect profile. Tamoxifen is the endocrine therapy of choice for premenopausal women, whereas strategies in postmenopausal women can include tamoxifen, AIs, or a sequential combination, with careful weighing of benefits and management of toxicity risks.

**Tamoxifen**

Tamoxifen, a hormonal agent approved for treatment of early breast cancer >30 years ago, is a selective ER modulator that interferes with estrogen binding to ER and in turn alters the expression of genes downstream from ER. The effects of the selective ER modulator/ER nuclear receptor transcription complex on gene transcription are determined by the presence and preferential binding of corepressors and coactivators in different tissues and account for their tissue-specific estrogen agonist and estrogen antagonist actions. In breast tissue, tamoxifen exhibits estrogen antagonist activity, and the competitive binding of tamoxifen to ER leads to the inhibition of estrogen-dependent tumor growth. ER antagonism is also the mechanism of some adverse effects of tamoxifen, including hot flashes and mood disturbances. However, in most organs, including the cardiovascular system, bone, and uterus, tamoxifen has
estrogen agonistic activity, which can result in beneficial or detrimental effects, depending on the affected tissue. Tamoxifen has a favorable effect on the lipid profile, with reductions in total serum cholesterol (in the range of 10% to 15%) and low-density lipoprotein cholesterol (reductions ranging from 15% to 22%), but no significant changes in HDL-C.224–227 Smaller studies reported increases in triglyceride levels in Asian patients treated with tamoxifen and raised concerns about hypertriglyceridemia,218,229 but the broader clinical relevance of these findings remains unknown. Despite observed favorable effects and the reductions in low-density lipoprotein cholesterol and total cholesterol levels, long-term data from clinical trials have failed to demonstrate a protective effect of tamoxifen with regard to hard cardiovascular end points. In the Early Breast Cancer Trialists’ Collaborative Group overview,219 which included 55 trials and 37,000 women, there was no difference in cardiac or vascular death between adjuvant and placebo groups. This was similar to the findings in the National Surgical Adjuvant Breast and Bowel Project B14,220 which reported only a small number of cardiac or vascular deaths, with no statistically significant difference between tamoxifen and placebo groups. These results indicate the need for caution in the interpretation of surrogate end points, such as lipid profile, which did not translate into a clinically relevant benefit of prevention of CVD death. Interesting comparisons have been made between findings in tamoxifen trials and the WHI study, which used HRT in postmenopausal women. From the lowering of low-density lipoprotein cholesterol and the increasing of HDL-C levels but also increased triglyceride levels in the WHI, HRT did not confer cardiovascular protection.162,222

In contrast to its protective effects on lipid metabolism, the estrogen-agonistic actions of tamoxifen resulted in a detrimental increase in thrombogenicity and increased risk of venous thrombosis and thromboembolism.233 Later studies that compared AI to tamoxifen demonstrated a reduced risk of thrombosis with AIs, presumably because of their lack of proestrogen effects. A meta-analysis of randomized adjuvant endocrine trials reported the incidence of thrombosis at 2.8% in the tamoxifen group compared with 1.6% in the AI group.234 Venous thromboembolism is associated with mortality and significant morbidity related to deep venous thrombosis, pulmonary embolism, and long-term sequelae such as pulmonary hypertension, which highlights the need to consider other risk factors (eg, history of stroke) when selecting endocrine therapy for women with ER-positive breast cancer.235

Aromatase Inhibitors
Als act by inhibiting the aromatase enzyme and depleting estrogen levels in postmenopausal women. Circulating estrogen is made in peripheral tissues from the conversion of androstenedione to estradiol via the enzyme aromatase in postmenopausal women.236 The 3 AIs currently in clinical use (anastrozole, letrozole, and exemestane) are third-generation agents characterized by high specificity and suppression of the aromatase enzyme, and their side-effect profiles mostly reflect the effects of estrogen depletion.237 AIs are recommended either as primary therapy or after 2 to 3 years of tamoxifen therapy (total duration, 5 years) in postmenopausal women with hormone receptor–positive breast cancer, to lower the risk of breast cancer recurrence.222 This recommendation is based on randomized controlled trials that continue to demonstrate reduced cancer recurrence rates and disease-free survival in postmenopausal women treated with AIs compared with tamoxifen.222,238–240 AIs have also been shown to be effective for primary prevention of breast cancer in high-risk postmenopausal women.241

Because AIs deplete endogenous estrogen production, it has been hypothesized that they might increase the risk of CVD, and most large adjuvant trials that have compared AIs to tamoxifen have included cardiovascular end points. Only a few large studies assessed hypercholesterolemia, and these yielded inconclusive results. The ATAC trial (Arimidex, Tamoxifen, Alone or in Combination)242 and the BIG (Breast International Group) I-98 trial239 reported a higher incidence of hypercholesterolemia with anastrozole and letrozole, respectively, than with tamoxifen, whereas the MA.17 trial did not find significant differences with letrozole.243 However, a meta-analysis of adjuvant AI trials that accounted for the duration of AI treatment and differences in treatment approach demonstrated that longer duration of AI use was associated with a statistically significant 2.3-fold increase in the OR for hypercholesterolemia compared with tamoxifen.244 The effect was most apparent when upfront AI use was compared with tamoxifen and least evident when switching from tamoxifen to AI was compared with tamoxifen.

In the same meta-analyses of adjuvant trials, a similar pattern of risk for CVD was observed: longer durations of AI use were associated with increased risk for CVD compared with tamoxifen use, with the effect being the strongest in the trials that evaluated upfront AIs versus upfront tamoxifen.243 In a pooled analysis, the OR for development of CVD with the use of AI compared with tamoxifen was 1.26 (CI=1.10–1.43; P<0.001), with an increase in absolute risk of 0.8% (4.2% versus 3.4% risk, respectively). Despite the small absolute risk, the clinical relevance of these findings could be high in specific populations at risk. In the ATAC trial, for example, in women with preexisting heart disease, the incidence of cardiovascular events was 17% in the anastrozole arm compared with 10% in the tamoxifen arm, which led to the US Food and Drug Administration (FDA) label recommendation that the risks and benefits of anastro-
Various adverse CVD effects have been demonstrated in trials comparing AI with tamoxifen; however, a randomized controlled trial comparing AI and placebo after 5 years of tamoxifen did not demonstrate any difference in CVD end points in early-stage breast cancer.

The results of population-based studies that investigated cardiovascular risk in postmenopausal women treated with AIs versus tamoxifen have also been mixed, but large studies have traditionally been limited by a lack of information about cardiovascular risk factors and medications. A recent analysis of 13273 postmenopausal women with endocrine-positive breast cancer in the Kaiser Permanente managed care system showed no association between AI use and risk of ischemia and stroke. Patients receiving AIs had a significantly higher risk of other forms of CVD (dysrhythmia, valvular dysfunction, pericarditis, HF, or cardiomyopathy), the significance of which requires further investigation. In a recent meta-analysis of AIs and tamoxifen in the adjuvant and extended adjuvant setting, significant CVD risk reduction was seen in patients treated with tamoxifen compared with placebo or no treatment in the adjuvant setting, and in the extended adjuvant setting, there was not an increased risk with AIs compared with placebo. These data suggest that the increased risk of cardiovascular effects of AIs compared with tamoxifen in randomized controlled trials might be secondary to the cardioprotective effects seen with tamoxifen.

**Ovarian Suppression Therapy**

Premenopausal women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy. In clinical studies, ovarian suppression was associated with a substantial increase in menopausal symptoms, sexual dysfunction, and diminished quality of life compared with tamoxifen alone but not cardiovascular specific side effects, which likely reflects the younger age and overall low cardiovascular risk profile of these patients. Longer follow-up will be needed to assess the effect of early menopause on cardiovascular risk, morbidity, and mortality in these patients.

**HER2-Targeted Therapies**

**Monoclonal Antibodies**

Trastuzumab and pertuzumab are the 2 current FDA-approved monoclonal antibodies that inhibit the signaling of HER2 (human epidermal growth factor receptor 2). LV dysfunction associated with targeted therapies has been most extensively evaluated in the breast cancer population treated with trastuzumab. Trastuzumab binds to the extracellular domain of the ErbB2 (erb-b2 receptor tyrosine kinase 2)/HER2 and leads to reduced ErbB2 signaling via several mechanisms. It has been speculated that the cardiac dysfunction associated with trastuzumab is a direct consequence of ErbB2 inhibition in cardiomyocytes. In contrast to anthracycline-induced cardiotoxicity, trastuzumab exposure can result in LV dysfunction and HF that is mostly reversible. At highest risk for cardiotoxicity from trastuzumab exposure are those >50 years of age, patients with underlying heart disease or hypertension, those with baseline LVEF between 50% and 55% or lower, and those who have also received anthracycline therapy (Table 2).

The introduction of adjuvant trastuzumab (with chemotherapy) for patients with HER2-positive early-stage breast cancer has reduced the risk of breast cancer recurrence by 50% and mortality by 33%. However, in the 5 major adjuvant trastuzumab trials, symptomatic, severe HF or cardiac events, with an incidence ranging from 0% to 3.9%, were observed with the addition of trastuzumab to traditional chemotherapy. Long-term follow-up data (median 8 years) after adjuvant chemotherapy in the international, multicenter, open-label, randomized HERA trial (HERceptin Adjuvant) of 5102 women demonstrated low overall cardiotoxicity, with a greater cumulative incidence of cardiotoxicity (4.1% versus 7.2% with New York Heart Association functional class I or II and significant drop in LVEF ≥10 points with absolute LVEF <50%) and no additional benefit in those treated with 2 years versus 1 year of trastuzumab therapy. Population-based studies, particularly in older individuals (women >65 years old), have suggested higher rates of cardiotoxicity. In a Surveillance, Epidemiology, and End Results program–based analysis of 9535 women (median age, 71 years) with early-stage breast cancer, of whom 2203 (23.1%) received trastuzumab, the rate of HF was 29.4% compared with 18.9% in nonusers of trastuzumab (P<0.001). Older age (age >80 years; HR, 1.53; 95% CI, 1.16–2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34–2.48), hypertension (HR, 1.24; 95% CI, 1.02–1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05–1.68) increased the risk of HF.

Current clinical trials in early breast cancer are taking advantage of the role of dual HER2 blockade, including the synergistic activity of pertuzumab and trastuzumab. Two neoadjuvant studies (NeoSphere and TRYPHAENA) demonstrated higher pathological complete response rates in women with HER2-positive breast cancer treated with chemotherapy and dual HER2 blockade (pertuzumab, trastuzumab) than in those treated with chemotherapy and trastuzumab therapy alone. In the TRYPHAENA study, the primary end point of cardiac safety was met, with a low incidence of symptomatic and asymptomatic LV systolic dysfunction across all arms. To date, there have not been any additional...
cardiac safety concerns when those agents were combined.266,267 In a recently published large, prospective, randomized trial (APHINITY trial) exploring trastuzumab with or without pertuzumab with adjuvant chemotherapy in the treatment of women with early-stage HER2-positive breast cancer, there was a low incidence of HF (0.7% in the pertuzumab group versus 0.3% in the placebo group, with HF defined as New York Heart Association functional class III or IV and a significant drop in LVEF ≥10 points with absolute LVEF <50%) and cardiac death (2 cardiac deaths in each arm).268

Small-Molecule Tyrosine Kinase Inhibitors
An alternative approach to inhibit HER2-mediated signaling is the use of small-molecule tyrosine kinase inhibitors that target the HER2 intracellular kinase domain. Lapatinib is a reversible small-molecule tyrosine kinase inhibitor that is frequently administered in combination with capecitabine or with endocrine therapy and is approved for the treatment of women with HER2-positive metastatic breast cancer.269,270 A phase III trial comparing lapatinib monotherapy versus combination therapy with trastuzumab demonstrated a 4.5-month survival advantage with combination therapy but also reported a higher incidence of serious adverse cardiac events of systolic dysfunction with combination therapy (6.7% versus 2%).271 Subsequently, the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) of 8381 women with early-stage breast cancer demonstrated no significant improvement in disease-free survival with adjuvant treatment that included lapatinib compared with trastuzumab monotherapy. Those treated with lapatinib experienced more noncardiac side effects (diarrhea, cutaneous rash, and hepatic toxicity), however, in all treatment arms, the incidence of cardiotoxicity was low (2%–3% for HF, 2%–5% for any cardiac event).272

Emerging Therapies
Cyclin-dependent kinase (CDK) 4/6 inhibitors are being developed to overcome endocrine resistance based on cross talk between ER pathways. CDK 4/6 is a group of serine/threonine kinases that accomplish their action by forming a complex with cyclin D. In turn, this complex phosphorylates the retinoblastoma protein and deactivates it, which results in gene transcription and progression of cell replication in the transition between the G1 and S process.273–275 In cancer, CDK 4/6 are upregulated and participate in tumor growth by blocking tumor suppression and apoptosis. Blocking the formation of CDK 4/6 cyclin D complex causes cell cycle arrest.276,277

The CDK 4/6 inhibitors that have been evaluated in the treatment of women with metastatic breast cancer are palbociclib, ribociclib (both approved by the FDA), and abemaciclib (pending approval by the FDA). All of these agents have been tested in phase II and III clinical trials and are administered in combination with endocrine therapy (eg, AI, fulvestrant). The clinical benefit of CDK 4/6 inhibitors in the treatment of women with metastatic breast cancer is beyond the scope of this review. The most common adverse events reported with these agents are bone marrow suppression (neutopenia, anemia, and thrombocytopenia), fatigue, vomiting, and diarrhea.277,278 Ribociclib is the only oral CDK 4/6 inhibitor for which there are cardiovascular concerns: prolongation of the corrected QT interval was seen in ≈9% of patients at doses of 600 mg/d (current approved dose in clinical practice) and in ≈33% at doses of >600 mg/d.279,280 This has led to the product label stipulating that ribociclib should be initiated only when the corrected QT interval is <450 ms and that electrocardiograms must be performed at baseline, on day 14, before starting cycle 2 (day 28), and then as clinically indicated.281 Healthcare professionals and patients should be educated about the importance of avoiding concomitant use of other drugs that could further prolong the QT interval.

Radiation Therapy
The biological mechanisms of RT cardiotoxicity remain incompletely understood but are most likely secondary to alterations in multiple pathways, including myocyte ischemia/injury, inflammation, fibrosis, oxidative stress, and microvascular dysfunction. Animal models of RT cardiotoxicity indicate that an inflammatory response is elicited within cardiac and endothelial cells, with increased adhesion molecule and cytokine activity.282 RT also results in increased reactive oxygen species in cardiac tissues.283 In the rodent heart, radiation causes microvascular endothelial damage, which leads to lymphocyte adhesion and extravasation. This is followed by thrombus formation and capillary loss. Progressive reduction in capillary patency eventually results in ischemia, myocardial cell death, and fibrosis. In vitro and in vivo studies demonstrate that RT has significant effects on the macrovasculature and microvasculature, causing myocardial ischemia and injury.284 In large blood vessels, such as the coronary and carotid arteries, RT causes inflammation and oxidative damage, which, in the presence of high cholesterol, leads to lipid peroxidation and the formation of foam cells that initiate the atherosclerotic process. RT results in accelerated atherosclerosis, with thickened and fibrotic media/adventitia.285 Myocyte fibrosis is a consequence of ischemia and has been observed in cardiac histopathological studies in animals with RT.285 Intriguing, emerging data suggest a cardioprotective role for mast cells in cardiac RT injury, through the kallikrein-kinin pathway.286–288

Thoracic RT carries a significant risk of CVD toxicity that results in increased morbidity and mortality,
which limits the critical gains in cancer control and survival. Cardiovascular effects secondary to coronary atherosclerosis and accelerated endothelial injury can occur as early as 5 years after exposure among breast cancer survivors who receive left-sided thoracic RT, and persistence of risk remains for up to 30 years. In addition to macrovascular disease, patients can also develop microvascular dysfunction that results clinically in impaired coronary flow reserve, myocardial ischemia, and myocardial fibrosis. A recent population-based case-control study demonstrated an increased risk in HF with preserved ejection fraction among women treated with contemporary breast cancer RT, which correlated with mean cardiac radiation dose. RT also increases the risk of anthracycline-induced cardiotoxicity. Acute and chronic pericarditis, valvular regurgitation and stenosis, and conduction abnormalities and sudden death are also well described, especially with chest radiation doses >30 Gy. Autonomic dysfunction is an underreported cardiovascular effect of RT that has an increased prevalence with higher radiation doses, and the associated impaired heart rate recovery significantly affects all-cause mortality.

In a study of 2168 women with breast cancer, each 1-Gy increase in mean heart radiation dose was associated with a 7.4% increase in coronary events. In a meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group of >23,000 women, there was an excess of non-breast cancer deaths after 5 years among patients receiving RT, principally attributable to CVD and lung cancer. Multiple epidemiological studies support these results. Mortality ratios defined by laterality of breast cancer in 558,871 women from the National Cancer Institute’s Surveillance, Epidemiology, and End Results program suggest that left-sided breast cancer patients treated with RT have a 1.19 to 1.90 increased risk of CVD mortality compared with those with rightsided breast cancer. Although some studies suggest that the CVD risks might be decreasing over time given improvements in treatment techniques, there is an important need for long-term data, particularly in the era of proton therapy. However, even with the use of modern techniques, including computed tomography planning and deep inspiration breath hold, incidental irradiation to smaller volumes of the heart results in cardiac perfusion defects.

**MONITORING FOR CARDIOVASCULAR TOXICITY**

**Early Identification of Risk**

LVEF obtained by echocardiography, multigated acquisition scan, or cardiac magnetic resonance imaging (MRI) is used to identify patients with cardiotoxicity; however, a change in LVEF could constitute a late manifestation of myocardial damage and might represent irreversible cardiac damage, thus emphasizing the need to predict cardiac damage before its occurrence. In addition, the limited accuracy and variability of 2-dimensional echocardiography (on the order of 10% in non-core laboratory quantitation settings) for LVEF assessment coupled with a lack of consensus of what constitutes a clinically significant reduction in cardiac function, suggest a critical need for a consensus for diagnostic and prognostic strategies. The variability in LVEF assessment can be of the same magnitude used to define cardiotoxicity in some settings. Furthermore, serial LVEF monitoring, although accepted, has never been validated in terms of outcomes. It is noteworthy that the sensitivity of 2-dimensional echocardiography for detection of small changes in LV function is low and is affected by changes in loading conditions associated with chemotherapy, which can then affect the LVEF value. As such, the development of strategies for early detection of cardiotoxicity has been the focus of more recent research efforts. In the clinical setting, these strategies thus far have fallen largely into 3 main categories: myocardial strain imaging, cardiac biomarkers, or a combination of imaging and biomarkers.

**Myocardial Strain Imaging for Risk Identification**

Speckle-tracking echocardiography for detection of LV myocardial strain is a newer cardiac imaging technique. It measures LV regional and global deformation in response to force as a marker of contractility and elasticity. Change in LV strain measures precedes change in LVEF and strain has been shown to be a predictor of cardiac dysfunction in breast cancer patients receiving chemotherapy. One study showed that an absolute longitudinal strain value of ≤17.2% obtained 6 months after anthracycline (doxorubicin or epirubicin) therapy was predictive of abnormal longitudinal strain at 1-year follow-up, with a sensitivity of 100% and specificity of 80%. Strain alterations were associated with higher doses of anthracyclines, although within the dose range considered to have an acceptable toxicity profile. Global longitudinal strain has also been shown to be an early predictor of subsequent LV systolic dysfunction in patients treated with trastuzumab. Studies by others have also demonstrated that longitudinal and circumferential strain have diagnostic and prognostic relevance in female breast cancer patients undergoing treatment with doxorubicin or trastuzumab.

Myocardial strain has excellent interobserver and intraobserver variability compared with other cardiac imaging modalities and is highly correlated with the relatively expensive and much less available cardiac MRI in the assessment of LV dysfunction. In addition,
strain imaging as obtained with echocardiography is less expensive and less time consuming, does not confer radiation risk to the patient, and is not nephrotoxic compared with other cardiac imaging modalities for LVEF assessment; however, echocardiography image acquisition can be significantly limited in the setting of obesity and lung disease.

**Biomarkers as Risk Markers of Chemotherapy-Induced Cardiac Disease**

The role of biomarkers in this setting lies in the prediction of cardiomyopathy or detection of subclinical cardiomyopathy. Studies have evaluated the role of cardiac biomarkers, particularly brain natriuretic peptide (BNP) and troponin I, which accurately reflect myocardial injury, in the evaluation of cardiotoxicity associated with breast cancer therapy.311,312

**Troponin I**

Troponin I is a well-established, highly sensitive and specific marker of myocardial injury with a wide diagnostic window and is a robust chemical assay.313 A rise in troponin-I within ≈3 days of high-dose chemotherapy has been shown to predict a reduction in LVEF.314 Troponin I has an excellent negative predictive value for not developing cardiotoxicity during and immediately after treatment. Additional studies have shown similar findings, with a negative predictive value of 90% for ruling out the possibility of doxorubicin-induced systolic dysfunction with troponin I.305 Troponin I has also been successful in differentiating reversible and irreversible LV dysfunction associated with trastuzumab,315 as well as in the identification of cardiovascular outcomes (defined as death resulting from a cardiac cause, acute pulmonary edema, overt HF, asymptomatic LVEF reduction ≥25% from baseline), or life-threatening arrhythmias) in patients receiving various types and combinations of high-dose chemotherapy. In contrast, it has also been demonstrated that troponin I increases were common in breast cancer patients receiving both trastuzumab and lapatinib but were not associated with subsequent LV dysfunction according to multigated acquisition scans.316

**Natriuretic Peptides**

There is a lack of consensus regarding the role of N-terminal pro-BNP (NT-proBNP) in breast cancer cardiotoxicity diagnosis and prognosis. Although some studies have shown that NT-proBNP did not predict cardiotoxicity in adults with breast cancer,316,317 others have supported the role of proBNP in the identification of these patients.318,319 Of note, in a group of patients in which most had received chemotherapy, BNP showed an area under the curve of 0.86 in the detection of asymptomatic LV systolic dysfunction.320 One study showed NT-proBNP to be more useful than troponin in the detection of subclinical LV dysfunction,321 and another showed that it predicted mortality at 1-year follow-up.322 Pitfalls associated with the use of natriuretic peptides include biological variation and variability with age, weight, renal function, and BMI. This calls for caution in the interpretation of data obtained using these serum markers.

**Novel Biomarkers in Risk Identification**

Data are limited on associations between novel biomarkers and cancer therapy–related cardiac dysfunction323–329; however, there are limited data in breast cancer patients. A small study in 78 patients with breast cancer undergoing doxorubicin and trastuzumab chemotherapy found that early changes in high-sensitivity troponin I and myeloperoxidase improved risk prediction of the first cardiotoxic event.330 Consideration was given to every cardiotoxic event and biomarker measure over the entire 15-month follow-up period, and myeloperoxidase, placental growth factor, and growth differentiation factor 15 were significantly associated with a risk of cardiotoxicity at the same and subsequent visits.331 Another study showed only NT-proBNP as a predictor of subclinical cardiotoxicity after treatment with anthracyclines.332

**Imaging Combined With Biomarkers**

Because both imaging and biomarkers are used as end points of the same pathological process, there could be value to using these methods conjointly to detect cardiotoxicity. In one study,317 a change in longitudinal strain and troponin I at 3 months after doxorubicin chemotherapy predicted cardiotoxicity at the 6-month follow-up. Cardiotoxicity was also predicted by the number of segments with change in longitudinal strain at 3 months. In another seminal article by the same group,305 the combination of a 10% decrease in longitudinal strain with elevation in troponin I predicted cardiotoxicity after doxorubicin therapy with a specificity of 97%, whereas either marker alone showed a sensitivity of 89% and a negative predictive value of 97% in detecting cardiotoxicity. The data therefore suggest possible benefit to the use of combinations of risk markers (strain imaging modality plus biomarkers in this case) in the identification of people at risk for cardiotoxicity after chemotherapy.

**Biomarkers in the Identification of Radiation-Induced Cardiotoxicity**

A few studies have evaluated biomarkers in patients undergoing RT with conflicting results. One early study of 50 women with breast cancer did not find any change in serum troponin after a total dose of 45 to 46 Gy of RT.333 Conversely, a more recent study of lung and breast cancer patients found both troponin and BNP increased significantly with radiation, although the ab-
solute and mean values remained at a relatively low level. In another recent study of 58 patients receiving RT for left-sided breast cancer, high-sensitivity troponin T increased during RT from baseline in 12 patients (21%). In that study, those patients with higher high-sensitivity troponin T values had received significantly higher radiation doses for the whole heart and LV than those with stable high-sensitivity troponin T values. Hence, cardiac biomarkers might be useful for evaluation of radiation-induced cardiotoxicity, but this requires further research before widespread implementation.

In recent times, the role of cardiac MRI in the detection of cardiotoxicity associated with cancer therapy has been studied. In addition to detecting an early subclinical decline in LVEF, cardiac MRI also has the ability to detect subtle changes in cardiac structure and to help identify the specific cause of abnormalities in LVEF. Thus, this is an imaging technique with a possible important role in detection of cardiotoxicity associated with cancer therapy; however, its specific role in this process is limited by associated costs and limited availability.

ONCOLOGIC STRATEGIES TO MITIGATE CARDIOTOXICITY

The multidisciplinary approach to the care of cancer patients exposed to multimodality cancer therapy has resulted in an increased understanding of the mechanisms of cancer therapy-related cardiotoxicity. This has led to the investigation and adoption of clinical approaches to mitigate the impact of cancer treatments on cardiovascular health.

Dexrazoxane

Dexrazoxane has been used as a chelating agent that binds to intracellular iron, thus decreasing free radical formation and reducing cardiomyocyte apoptosis. Similar cardioprotection has not been achieved with other iron-binding agents, however, and more recent work suggests that dexrazoxane changes the conformation of topoisomerase IIβ and interferes with anthracycline binding. Multiple trials conducted in breast cancer patients undergoing chemotherapy with doxorubicin or epirubicin showed significant reductions in the combined end point of decrease in LVEF or development of HF with the addition of dexrazoxane and follow-up intervals that ranged from 15 to 43 months. A meta-analysis of 7 trials (1000 patients) estimated an overall reduction in cardiac events of 65% (RR, 0.35; 95% CI, 0.27–0.45) with dexrazoxane versus placebo. Others estimated a 79% reduction in clinical HF when dexrazoxane was included in the treatment regimen (RR, 0.21; 95% CI, 0.13–0.33). The most recent Cochrane database concluded on the basis of 8 trials that dexrazoxane use was associated with an 82% reduction in HF (RR, 0.18; 95% CI, 0.1–0.32), with no impact on progression-free survival, overall survival, or cancer response rates (RR, 0.89; 95% CI, 0.78–1.02, P=0.08). Because of persistent uncertainty about the risk of secondary malignancies (primarily based on long-term follow-up of pediatric patients) and possibly reduced tumor response rates, the FDA indication for dexrazoxane is quite narrow in breast cancer patients. Dexrazoxane is “indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy to maintain tumor control. It is not recommended for use with the initiation of doxorubicin therapy.” The American Society of Clinical Oncology has issued similar guidance. The European Medicines Agency has expanded the usage to include patients who have a received a minimum cumulative epirubicin dose of 540 mg/m².

Doxorubicin Administration

Although total cumulative dose administered appears to be the strongest predictor of subsequent cardiotoxicity, rate of infusion (presumably representing peak plasma level) also has a significant impact. Administration of doxorubicin via infusion as opposed to bolus administration is associated with a significant decrease in the risk of symptomatic cardiotoxicity without loss of antitumor efficacy (OR, 4.13; 95% CI, 1.75–9.72 for bolus administration versus infusion). A Cochrane database meta-analysis of 6 trials involving 735 patients showed a 73% reduction in clinical HF with infusion duration of ≥6 hours compared with shorter duration of infusion (RR, 0.27; 95% CI, 0.09–0.81; P=0.02) without significant heterogeneity among trials. Only 1 of these studies reported on LVEF and demonstrated lesser declines with the prolonged infusion at cumulative doses of 300 and 400 mg/m². Clinical HF rates and survival did not differ in 2 studies that compared peak doses of ≥60 mg/m² with peak doses of <60 mg/m². Doxorubicin administered via continuous infusion (up to 48–96 hours) is not widely used because of practical issues requiring hospital admission. Liposomal (pegylated or nonpegylated) formulations of doxorubicin permit delivery of a higher cumulative dose with preserved efficacy but a lower rate of cardiac side effects (OR, 0.18; 95% CI, 0.08–0.38). This favorable ratio of benefit and adverse effect is attributed to ready penetration through the vasculature within the tumor tissue, whereas the liposomes tend to remain in the intravascular space in other organs, including the heart.
do not carry an indication for breast cancer, but they are approved for secondary therapy in ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma.248

**Radiation Techniques**

Newer radiation techniques (proton therapy, deep-inspiration breath holding, respiratory gating, lateral decubitus position, or use of modern 3-dimensional planning) have been devised that limit radiation dose overall and dose per fraction and limit the volume of heart exposed to radiation.347–349 These newer techniques are likely to be associated with lower complication rates, but long-term follow-up data are not available at this time.

**PREVENTIVE THERAPIES**

The risk-benefit profile of each patient must be taken into consideration when choosing chemotherapy that can potentially cause cardiotoxicity, particularly in patients who, a priori, are considered to be at high risk for myocardial damage. Close collaboration between the oncologist and cardiologist is essential (Figure 4 provides a simplified approach to the detection, prevention, and treatment of HF in breast cancer patients). There are no definitive guidelines specific to CVD prevention in breast cancer patients, because most of these studies were small and had variable end point definitions. Nevertheless, the next section will review CVD medications that could be used from a preventive standpoint for CVD or breast cancer, the role of exercise in the breast cancer patient, and CVD prevention in breast cancer survivorship.

**β-Blockers and Renin-Angiotensin-Aldosterone System Blockade**

Small randomized, placebo-controlled trials have shown benefit of prophylactic β-blocker (BB) therapy in breast cancer patients. Two trials, one predominately of breast cancer patients and the other solely of breast cancer patients, showed less of a decline in LV function at 6 months with prophylactic BB therapy (carvedilol or nebivolol) than with placebo before the initiation of anthracycline-based chemotherapy.351,352 Another study found that breast cancer patients with structurally normal hearts at baseline who were treated with anthracycline or trastuzumab and who were taking a BB during treatment had a lower incidence of new HF events.353 Conversely, a retrospective study of 179 patients receiving adjuvant trastuzumab for early breast cancer found that BB and angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use did not alter the risk of trastuzumab-induced cardiotoxicity.354 In balance, the data are mixed about whether and which type of prophylactic BB should be started in patients before the initiation of breast cancer therapy involving anthracycline or trastuzumab. PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) was a 2×2 factorial randomized, double-blind, placebo-controlled trial in patients with early breast cancer who had surgery and were scheduled for adjuvant chemotherapy (5-FU, epirubicin, and cyclophosphamide). Patients received a combination of candesartan, metoprolol succinate, and placebo. A modest reduction in LV function was attenuated with candesartan (0.8% versus 2.6% in the placebo group, P=0.026), but metoprolol succinate showed no effect on overall

---

*Figure 4. Simplified depiction of detection, prevention, and treatment of left ventricular systolic dysfunction in breast cancer.*

Schematic of the continuum of breast cancer treatment in relation to subsequent cardiac toxicity and heart failure. ACC indicates American College of Cardiology; ACE, angiotensin-converting enzyme; AHA, American Heart Association; CV, cardiovascular; LVEF, left ventricular ejection fraction; and MUGA, multigated acquisition. Modified from Khouri et al.350 Copyright © 2012, American Heart Association, Inc.
LVEF decline. The more recently published MANTI-CORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research) 101–Breast trial was a randomized, placebo-controlled, double-blind trial in patients with HER2-positive early breast cancer who were being treated with trastuzumab adjuvant therapy. During the entire duration of adjuvant therapy, they also received treatment with either perindopril, bisoprolol, or placebo (1:1:1). There was a small decline in LVEF in the placebo group (5%), whereas the decline in LVEF was attenuated to 3% in the ACE inhibitor group and 1% in the BB group. However, neither pharmacotherapy prevented the primary end point of trastuzumab-mediated LV remodeling, which was defined as the change over time in indexed LV end-diastolic volume on cardiac MRI. Neither of these studies reported on HF outcomes, perhaps because of insufficient statistical power.

During treatment, early initiation of HF therapy for anthracycline-induced cardiomyopathy is beneficial. In a study of 201 patients with anthracycline-induced cardiomyopathy regardless of HF symptoms, 74% received maximally tolerated doses of enalapril and carvedilol, whereas the rest tolerated only enalapril. The majority of patients had breast cancer. A decreased time to HF treatment and low New York Heart Association functional class were independent predictors of LVEF recovery. This group went on to show, in a cohort of 2625 cancer patients, that =9% developed anthracycline-induced cardiomyopathy, 88% of whom developed a decline in LVEF within 1 year of treatment (median, 3 months). Early detection of anthracycline-induced cardiotoxicity and treatment with HF therapy was associated with LVEF improvement. In a smaller study of 25 patients with doxorubicin-induced cardiomyopathy, the majority of whom had breast cancer, those treated with a combination of an ACE inhibitor and a BB had significant improvement in LVEF, which was not seen with ACE inhibitor treatment alone.

BBs have been associated with recovery of LV function in trastuzumab-induced cardiomyopathy. In a retrospective study of 499 women receiving adjuvant trastuzumab for early-stage breast cancer, the combined use of an ACE inhibitor and a BB was independently associated with hypertension and a significant decline in LVEF from baseline at 3 months. However, this association is confounded by indications for antihypertensive therapy, and those on combined therapy were significantly older, with worse baseline clinical profile (higher rates of history of hypertension and dyslipidemia). Interestingly, the combined use of an ACE inhibitor and a BB was also associated with LVEF recovery from 3 to 12 months, which suggests that these drugs are beneficial in cardiac recovery. In a study of 38 women with suspected trastuzumab-induced LV dysfunction, once HF symptoms and LVEF were stable after treatment with trastuzumab ended, 25 women who were given maximally tolerated doses of ACE inhibitor and BB were rechallenged with trastuzumab, and 22 (88%) had a stable LVEF without HF symptoms in follow-up. It is not clear how many women were taking an ACE inhibitor or BB at baseline; however, this series also suggests the combined use of an ACE inhibitor and BB can lead to LV systolic recovery. In 247 consecutive patients, the majority with breast cancer, interventions such as the initiation of cardiac medications, which included BBs in 80% of cases, were associated with a significant improvement in mean LVEF but not a return back to baseline. For trastuzumab cardiotoxicity, the European Society of Medical Oncology and the Canadian Trastuzumab Working Group recommend initiation of an ACE inhibitor and BB in patients with HF and LVEF <40%; they also recommend an ACE inhibitor in all asymptomatic patients with LVEF <40%, and recommend that a BB should be considered in asymptomatic patients with LVEF <40%. The Canadian Cardiovascular Society’s guidelines recommend ACE inhibitor/ARB and BB combination therapy in cancer patients with an LVEF <40%, and these therapies should also be considered in those with an asymptomatic decline in LVEF (<10% decrease from baseline or LVEF <53%).

Observational studies suggest that BB use can influence breast cancer mortality or recurrence. A retrospective study of 466 female patients with operable breast cancer and follow-up >10 years showed that patients taking a BB had a significant reduction in the development of metastasis and tumor recurrence and had longer disease-free survival. A meta-analysis of 46265 breast cancer patients showed significant breast cancer–specific survival in patients treated with a BB. A similar observational study demonstrated that BB use was associated with a lower risk of breast cancer recurrence and cause-specific mortality. Another retrospective study of 1413 breast cancer patients showed BB use was associated with significantly better relapse-free survival, including in patients with triple-negative breast cancer. Other studies have shown that breast cancer patients treated with propranolol are significantly less likely to present with advanced disease and have a significantly lower cumulative probability of breast cancer–specific mortality compared with matched nonusers. Conversely, a cohort study of 4126 women with early-stage breast cancer in an integrated health plan showed BB use carried an increased risk of recurrence, whereas a nationwide study of Danish breast cancer survivors showed BBs did not attenuate recurrence risk. However, there are confounding factors in all of these studies, and thus, there is a need for a large randomized controlled trial to elucidate the potential benefit of BBs, ACE inhibitors, and ARBs in breast cancer survivorship.

ACE inhibitors have been the agents best studied to prevent or treat LV dysfunction, whereas ARBs are less...
well studied in this area. With the increased role of the mineralocorticoid antagonists in HF, including HF with preserved ejection fraction, and its potential to diminish fibrosis, spironolactone would be a logical protective agent. At least 1 study has shown that when spironolactone is used concomitantly with an anthracycline drug in breast cancer patients, the decline in ejection fraction was attenuated in addition to diastolic stabilization.371 This drug could have tremendous potential, and further studies are required. Although data from large randomized controlled trials of BB, ACE inhibitor/ARB, and spironolactone use in breast cancer patients are not yet available, it seems reasonable to treat anthracycline or trastuzumab-induced cardiomyopathy in accordance with the American College of Cardiology/American Heart Association HF guidelines.372,373

Aspirin
A number of observational studies have suggested a possible benefit of regular aspirin use in the prevention of breast cancer. A 2008 study found a strong protective effect of regular aspirin use and breast cancer. In that study, the investigators reported that taking low-dose aspirin ≥4 d/wk over 10 years decreased the risk of breast cancer by 35% (HR, 0.65; CI, 0.43–0.97).374 A 2011 study analyzed data from 26,580 postmenopausal women 59 to 77 years of age, 1,581 of whom were diagnosed with breast cancer. These investigators found that women who regularly took aspirin had a 20% lower risk of developing breast cancer (RR, 0.80; 95% CI, 0.71–0.90). They further found that the risk decreased with increasing frequency of use, with a risk reduction of 29% in women taking aspirin ≥6 times per week compared with those who never took aspirin (RR, 0.71; P for trend=0.00001).375

Other trials, however, have found less or no protective effect of regular aspirin use and prevention of breast cancer. A 1996 report using data from the NHS found no protective effect against breast cancer for those taking regular aspirin. These investigators further analyzed aspirin use in 2,414 cases of invasive breast cancer and again, in this subset of patients, found that regular aspirin use was not associated with prevention of breast cancer.376

A few studies have suggested an increased risk of breast cancer among women taking regular aspirin. Data from a Danish cohort demonstrated regular aspirin use actually increased risk of breast cancer by 38% (RR, 1.38; 95% CI, 1.12–1.69).377 They found a nonsignificant increase in risk of recurrence of breast cancer in women taking aspirin.378 A large study on the role of aspirin in breast cancer prevention was the Women’s Health Study, published in 2005.379 This was a randomized, placebo-controlled trial of 39,876 women ≥45 years old who were randomly assigned to take either 100 mg of aspirin every other day or placebo. After 10 years of follow-up, no protective effect was seen in breast cancer (RR, 0.98; 95% CI, 0.87–1.09; P=0.68).

Although these individual studies do not provide strong support for aspirin use to prevent breast cancer, several meta-analyses did find a reduction in breast cancer incidence with regular aspirin use. One of the most important meta-analyses included data from 38 studies including 2,788,715 women and reported that regular aspirin use reduced risk of breast cancer by 13% (RR, 0.87; 95% CI, 0.82–0.92).380 There is clearly equipoise about the question of whether regular aspirin use prevents incident or recurrent breast cancer, and an ongoing placebo-controlled, randomized trial is expected to answer the latter question.

Statins
An early statin trial, the CARE trial (Cholesterol and Recurrent Events)382 reported the unexpected finding of an increased incidence of breast cancer in those assigned to statin therapy. However, these findings were thought to be spurious and an anomaly owing in part to a very low incidence of breast cancer cases in the placebo group and an imbalance in risk factors for breast cancer at baseline. No other statin trials have found an association or an increased risk,381 and other investigators had surmised that statins might exert a beneficial effect and a reduction of cancer incidence, perhaps via inhibition of cell proliferation by systemic cholesterol reduction. However, a meta-analysis of 7 randomized controlled trials and 9 observational studies, with a total of 7,858 breast cancer cases, found no association between statin use and breast cancer incidence.384,385 Additionally, data from 24 observational studies with 76,759 total breast cancer cases,385 showed no association between statin use and breast cancer incidence (RR, 0.99; 95% CI, 0.94–1.04). Finally, the WHI program studied 154,587 postmenopausal women 50 to 79 years of age and identified 7,430 pathologically confirmed cases of breast cancer over an average follow-up of 10.8 years.386 They also found no association between statin use and breast cancer risk; the annualized rate of breast cancer was 0.42% among statin users and 0.24% among nonusers, and the multivariable adjusted HR of breast cancer for users versus nonusers was 0.94 (95% CI, 0.83–1.06).

Despite no evidence for an effect of statins on breast cancer incidence, there is some evidence that statins might favorably impact breast cancer prognosis. One such study was conducted on patients ≥2 years after a breast cancer diagnosis who were then followed up for 5 years.387 Using data on medication use from the pharmacy records of the Kaiser Permanente Health System, the adjusted HR for developing a recurrence of breast cancer in statin users versus nonusers was 0.67 (95% CI, 0.39–1.13). Another larger cohort study of Danish breast cancer patients found similar results with lipophilic statins.388 Interestingly, there are also ongoing
studies evaluating a potential cardioprotective effect of statin therapy on anthracycline-induced cardiomyopathy and HF. Clearly, more data are needed on the potential protective effects of statin therapy.

Exercise
The vast majority of studies investigating exercise prevention of cancer treatment–induced cardiovascular toxicity are in rodent models, but there are limited data in humans. A single-arm study investigated the effects of 4 months of exercise training in 17 breast cancer survivors receiving adjuvant trastuzumab therapy and found that despite exercise training, trastuzumab was associated with LV dilatation and reduced LVEF. However, the exercise training intensity might have been insufficient, because participants attended only 59% of prescribed sessions. In a multicenter randomized controlled trial in Canada conducted between 2003 and 2005, 242 breast cancer patients initiating anthracycline-based adjuvant chemotherapy were randomized to usual care, supervised resistance exercise, or supervised aerobic exercise for the duration of their chemotherapy (median, 17 weeks; 95% CI, 9–24 weeks). Although adherence to prescribed exercise was high (70.2%) and the study demonstrated improvement in self-esteem, reduced percent body fat with aerobic exercise, and improved muscular strength, lean body mass, and chemotherapy completion rate with resistance training, no cardiovascular end points were assessed.

An analysis of 2 large-scale prospective cohort studies in 2973 women with nonmetastatic breast cancer demonstrated a strong, graded inverse relationship between exercise intensity and incidence of cardiovascular events in general, as well as for the incidence of coronary artery disease and HF in particular. The benefit emerged in those with an exercise level of ≥10 metabolic equivalent h/wk, which matches the national exercise guidelines for adult patients with cancer (≥2 metabolic equivalent h/wk), and resulted in a 23% lower risk of cardiovascular events, 26% lower risk of coronary artery disease, and 29% lower HF risk in the study cohort. Further clinical research is needed to determine whether exercise during cancer therapy is a feasible and effective method for the reduction of cardiovascular morbidity and mortality in breast cancer survivors. There are 2 ongoing trials examining the role of exercise in breast cancer patients receiving chemotherapy. TITAN (Multidisciplinary Team Intervention in Cardio-Oncology) is a randomized controlled trial that will compare the effects of intensive multidisciplinary team interventions (nutritional counseling, exercise training, etc) with usual care for prevention of LV remodeling in patients with newly diagnosed early breast cancer or lymphoma who are scheduled for anthracycline-, trastuzumab-, or anthracycline and trastuzumab–based chemotherapy. OptiTrain is a randomized controlled trial that will assess the effects of different exercises (aerobic training, combined resistance and aerobic exercise training) versus usual care on the physical and mental health of breast cancer patients undergoing chemotherapy.

Survivorship Programs
Improvements in cancer treatment have resulted in an increasing number of long-term cancer survivors who could have their survival and quality of life affected by concomitant CVD. Cardiovascular comorbidity can be preexisting or secondary to toxicity related to cancer therapy. Secondary prevention in the context of breast cancer relates to the management of preexisting cardiovascular risk factors and monitoring for cardiotoxicity during the survivorship period after breast cancer treatment has been completed. An initial step in deciding the medical approach in the survivorship stage is to determine risk of CVD. Breast cancer survivors at higher risk for CVD include patients with any cardiovascular abnormality noted in follow-up or patients who received doxorubicin >240 mg/m², radiation >30 Gy, radiation plus anthracycline, or high-dose cyclophosphamide, particularly if strenuous activity or pregnancy is planned. Medical treatment of left ventricular dysfunction in patients with cancer generally follows the American Heart Association/American College of Cardiology HF guidelines with some modifications adapted for patients with the high-risk factors mentioned above. Importantly, treatment recommendations will need to be individualized to the overall survival prognosis of the breast cancer patients.

Traditional cardiovascular risk factors, namely, hypertension, diabetes mellitus, dyslipidemia, and lifestyle, among others, will need to be assessed in survivorship programs. Management of blood pressure, glucose, and hypercholesterolemia and treatment of tobacco abuse should follow current American Heart Association Guidelines. The use of statins in patients with breast cancer includes the same indications as in primary prevention of CVD.

In women with breast cancer, treatment and the disease itself contribute to weight gain and to decreases in physical activity. Furthermore, it has been reported that cardiopulmonary function in patients with breast cancer improves with exercise, and regular exercise results in an improvement in quality of life. Although the usefulness of exercise to prevent CVD in patients with breast cancer has not been evaluated in randomized trials, it is reasonable to follow the American Heart Association recommendations for physical activity, that is, moderate-intensity aerobic physical activity of ≥30 minutes 5 days each week.
tion, a recent meta-analysis of studies that examined all the effects of physical activity on the risk of breast cancer recurrence and mortality found that prediagnosis and postdiagnosis physical activity were both associated with a lower mortality and cancer recurrence rate, which supports the idea that physical activity reduces these events among breast cancer survivors.115

**Posttreatment Cardiac Imaging Surveillance**

Long-term surveillance aims at monitoring those with preexisting and ongoing CVD and those at risk for late cardiotoxicity, particularly those who received anthracyclines and mediastinal RT.196,197 Longer-term data suggest modest but persistent declines in LVEF with exposure to common cancer therapies, as well as an increase in measures of arterial and chamber stiffness,186 possibly suggestive of HF with preserved ejection fraction. Accordingly, most guidelines or expert consensus documents recommend surveillance imaging during breast cancer imaging and possibly posttreatment depending on agent and dose administered. A consensus document for multimodality imaging in adult cancer patients by the American Society of Echocardiography and the European Association of Cardiovascular Imaging recommends the evaluation of cardiac function (typically echocardiography and, if suboptimal, then cardiac MRI) at baseline, at completion of therapy, and at 6-month follow-up in patients receiving anthracycline therapy at cumulative doses <240 mg/m²; those with higher cumulative doses should have repeat LVEF measurement before each additional dose of 50 mg/m², and any patient with LVEF <53% is recommended to have a cardiology consultation. Those receiving HER2-targeted therapies are recommended to undergo a baseline evaluation of LVEF, and then an LVEF evaluation every 3 months during therapy; however, those who were previously treated with an anthracycline should have LVEF reassessed 6 months after completion of HER2-targeted therapies (Figure 5). Additionally, after completion of breast cancer treatment, it was recommended that patients undergo annual cardiovascular assessments by a provider; however, cardiac imaging should be at the discretion of the provider, based on the history and physical examination.408

A subsequent expert consensus publication proposed that in low-risk patients, a transthoracic echocardiogram with strain be performed at the completion of therapy, with no need for further follow-ups if the test result is normal and the patient remains asymptomatic. In contrast, for patients at medium to high risk, a transthoracic echocardiogram with strain is recommended (1) only at completion of therapy for patients with cardiotoxicity as seen with agents such as trastuzumab, or (2) at completion of therapy and then at 6 to 12 months or 12 and 18 months after treatment among patients receiving anthracyclines alone or in combination with trastuzumab and RT; however further surveillance recommendations were not established.409 The American Society of Clinical Oncology practice guidelines for prevention and monitoring of LV dysfunction in adult cancer patients propose that all patients formerly treated with potentially cardiotoxic therapies undergo a detailed history and physical examination, and
if there are any signs or symptoms of LV dysfunction, then further testing, including imaging assessment with echocardiography (or cardiac MRI or multigated acquisition), is recommended. Asymptomatic patients with a presumed elevated risk of potentially developing LV dysfunction may undergo imaging 6 to 12 months after completion of cancer therapy; however, if results are normal, there are no current recommendations regarding frequency of subsequent surveillance in these patients.11 These 3 different approaches reflect the knowledge gaps and uncertainty around the progression and natural course of these complications. Although more data are needed, it is reasonable to consider long-term imaging surveillance, and the decision should be a clinical decision (taking into account the history and physical examination), with the risks and benefits of further testing to be weighed by the clinician.408

FUTURE DIRECTIONS

As the population ages, there will likely be more women with breast cancer, CVD, or both. Current cancer treatments might increase the risk of both short- and long-term cardiotoxicity, and women who are breast cancer survivors could be at higher risk of death caused by CVD than women without a history of breast cancer. More research is needed in terms of optimal surveillance of cardiotoxicity, preventive therapies, and treatment of cardiotoxicity. There are gaps in care and in priorities that would help bridge care of the patient (Table 3). Improved risk assessment and development of personalized preventive strategies in cancer survivorship programs are imperative for improved outcomes and reductions in CVD mortality in the breast cancer patient. Over the past decade, the number of cardio-oncology programs has increased, but many are centered on the treatment of CVD secondary to cancer therapies, and less emphasis has been placed on prevention before development of cardiotoxicity. Clearly, there are common risk factors between breast cancer and CVD. The care of these patients extends beyond the silos of cardiology and oncology and should be interdisciplinary, with vigilance with regard to the primary prevention of CVD along with the secondary prevention of CVD.

Currently, several organizations, such as the American College of Cardiology (Cardio-Oncology Section), Canadian Cardiac Oncology Network, European Society of Cardiology, European Society of Medical Oncology, and the International Cardio-Oncology Society, are working on initiatives to promote collaboration of healthcare professionals from oncology and cardiology disciplines and to improve the care of cancer patients who are treated with potentially cardiotoxic therapies. Additionally, there must be standardization of nomenclature regarding cardiotoxicity, as well as training of the future generation of care providers.

Table 3. Future Directions in Care of Breast Cancer and CVD Patients

<table>
<thead>
<tr>
<th>Gaps in care</th>
<th>Priorities to improve outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>What are more the effective predictors of cardiotoxicity?</td>
<td>Improved screening and risk factor assessment in oncology patients</td>
</tr>
<tr>
<td>Are there genetic or genomic variabilities that impact the risk of developing cardiotoxicity?</td>
<td>Development of targeted therapies with limited CVD adverse impact</td>
</tr>
<tr>
<td>What are the determinants of racial disparities in outcomes?</td>
<td>Better understanding of combined chemotherapy and radiotherapy adverse effects on CVD</td>
</tr>
<tr>
<td>With advancements in radiotherapy, what are the radiation thresholds and alternative techniques to avoid the development of CVD toxicity?</td>
<td>Earlier detection of CVD effects: imaging, biomarker, or clinical predictive models</td>
</tr>
<tr>
<td>Do newer breast cancer therapies substantially affect CVD risk?</td>
<td>Consistency in terminology of cardiovascular effects and then incorporation in trials as end point measures for CVD outcome</td>
</tr>
<tr>
<td>What are the effects of risk factor modification on CVD outcomes in cancer patients?</td>
<td>Formal guidelines for primary and secondary prevention of cardiotoxicity</td>
</tr>
<tr>
<td>What are pharmacological mechanisms to prevent or reverse cardiotoxicities of cancer therapy?</td>
<td>Reduction in racial disparities in CVD outcomes with increase access to care</td>
</tr>
<tr>
<td></td>
<td>Need for national or international database on cardiovascular and oncologic outcomes</td>
</tr>
</tbody>
</table>

CVD indicates cardiovascular disease. Adapted with permission from Armenian et al.11 © 2017. American Society of Clinical Oncology. All rights reserved.

CONCLUSIONS

Ideal breast cancer outcomes are reliant on coexisting cardiovascular health along the entire journey of breast cancer treatment. At the time of initial presentation, cardiac risk factors and preceding CVD can impact cancer treatment options. During breast cancer treatment, surveillance, prevention, and secondary management of cardiotoxicity are crucial; thereafter, long-term posttreatment monitoring for late cardiotoxicity and even non–treatment-related development of CVD is essential. With the evolving intersection of the cardiovascular and oncologic fields, comprehensive care is an essential element in the management of cancer patients to maximize gains in cancer treatment while minimizing the potential deleterious impact on cardiovascular health.

ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and
submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on November 1, 2017, and the American Heart Association Executive Committee on December 11, 2017. A copy of the document is available at http://professional.hear.org/statements by using either “Search for Guidelines & Statements” or the “Browse by Topic” area. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Piña IL, Volgman AS; on behalf of the American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137:e1-–e40. DOI: 10.1161/CIR.0000000000000556.

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://professional.hear.org/statements. Select the “Guidelines & Statements” drop-down menu, then click “Publication Development.”

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page.

### Disclosures

#### Writing Group Disclosures

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/ Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laxmi S. Mehta</td>
<td>The Ohio State University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Karol E. Watson</td>
<td>University of California, Los Angeles</td>
<td>None</td>
<td>None</td>
<td>Boehringer Ingelheim†</td>
<td>None</td>
<td>None</td>
<td>Amarin*; Amgen*; Boehringer Ingelheim*</td>
<td>None</td>
</tr>
<tr>
<td>Ana Barac</td>
<td>MedStar Heart &amp; Vascular Institute, MedStar Washington Hospital Center</td>
<td>Genentech, Inc (Cardiology PI on SafeHEArT, no financial compensation or support of salary)*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Theresa M. Beckie</td>
<td>University of South Florida</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vera Bittner</td>
<td>University of Alabama at Birmingham</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Salvador Cruz-Flores</td>
<td>Texas Tech University, Health Sciences Center</td>
<td>AstraZeneca (SOCRATES trial)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Duke University*; Lilly*; NovoNordisk*; Pharmacosmos; Sunovion*</td>
<td>None</td>
</tr>
<tr>
<td>Susan Dent</td>
<td>The Ottawa Hospital Cancer Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Hoffman La Roche*; Novartis*</td>
<td>None</td>
</tr>
<tr>
<td>Lavanya Kondapalli</td>
<td>University of Colorado</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bonnie Ky</td>
<td>University of Pennsylvania</td>
<td>NIH (R01 funding)†; Roche (investigator-initiated for biomarker evaluation in cancer therapy)*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Roche*</td>
<td>None</td>
</tr>
<tr>
<td>Tochukwu Okwuosa</td>
<td>Rush University Medical Center</td>
<td>Brian Piccolo Cancer Research Fund/Gavers Community Cancer Foundation (pilot research award)†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ileana L. Piña</td>
<td>Montefiore Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Annabelle Santos Volgman</td>
<td>Rush University Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Significant.

†Significant.

Modest.
## Reviewer Disclosures

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/ Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joerg Herrmann</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Daniel Lenihan</td>
<td>Vanderbilt U</td>
<td>Takeda</td>
<td>cardiac safety with cancer therapy/†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric Yang</td>
<td>UCLA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.
†Significant.

## REFERENCES


Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association

Laxmi S. Mehta, Karol E. Watson, Ana Barac, Theresa M. Beckie, Vera Bittner, Salvador Cruz-Flores, Susan Dent, Lavanya Kondapalli, Bonnie Ky, Tochukwu Okwuosa, Ileana L. Piña, Annabelle Santos Volgman and On behalf of the American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research

_Circulation._ published online February 1, 2018;

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2018 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circ.ahajournals.org/content/early/2018/01/31/CIR.0000000000000556

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/